Skip to main content
OpenTrials
Completed

NCT Number: NCT03923855

Clinical Evaluation of the BTL-899 Device for Non-invasive Lipolysis on Human Fat Tissue

The subjects will be enrolled and assigned to a single study group. They will be required to complete two treatment visits and come for a biopsy procedure.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dr. Denkova Dermatology

Sofia, 1700, Bulgaria

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age above 21 years and below 60 years
  • Voluntarily signing of the informed consent form
  • Women of child-bearing potential are required to use birth control measures during the whole duration of the study
  • Eligibility to fat tissue biopsy at surgeon discretion, incl. at least 3-4 cm pinchable fat in the abdominal area
  • Subjects willing and able to abstain from partaking in any procedure to promote body contouring during study participation
  • Subjects willing and able to maintain his/her regular (pre-procedure) diet and exercise regimen without effecting significant change in either direction during study participation

Exclusion criteria

  • Electronic implants (such as cardiac pacemakers, defibrillators and neurostimulators)
  • Cardiovascular diseases
  • Disturbance of temperature or pain perception
  • Pulmonary insufficiency
  • Metal implants
  • Drug pumps
  • Malignant tumor
  • Hemorrhagic conditions
  • Septic conditions and empyema
  • Acute inflammations
  • Systemic or local infection such as osteomyelitis and tuberculosis
  • Contagious skin disease
  • Elevated body temperature
  • Pregnancy
  • Breastfeeding
  • Injured or otherwise impaired muscles
  • Scars, open lesions and wounds at the treatment area
  • Basedow's disease
  • Previous liposuction in the treatment area in the last six months
  • Abdominal wall diastasis
  • Unstable weight within the last 6 months (change in weight ± 3%)
  • Previous body contouring treatments in the abdomen area in the last three months
  • Any disease or condition contradicting the fat tissue biopsy at the surgeon discretion
  • Any disease or condition that may compromise the histologic observation at the pathologist discretion

Treatment and study plan

BTL-899

Device

BTL-899 therapy

Primary outcomes

  1. Histology Examination

    Time frame: 4 months

    Histological examination of the fat tissue after BTL-899 treatment at various days after the procedure

  2. Evaluation of Satefy: Occurence of adverse events throughout the study

    Time frame: 4 months

    Following the occurence of adverse events throughout the study.

Sponsors and collaborators

Lead sponsor

BTL Industries Ltd.

Industry

Registry information

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Apr 23, 2019
Registry last updated
Dec 20, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.